Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Virax Biolabs Group Limited (VRAX : NSDQ)

• Company Description    Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, and diagnosis of viral diseases as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. Virax Biolabs Group Limited is based in London, United Kingdom. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $0.89 Daily Weekly Monthly 20 Day Moving Average: 43,327 shares Shares Outstanding: 4.34 (millions) Market Capitalization: $3.86 (millions) Beta: 1.65 52 Week High: $7.63 52 Week Low: $0.74 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.28% -10.75% 12 Week -10.41% -24.64% Year To Date -60.44% -62.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL BioCity Glasgow Bo Ness Road Newhouse - Lanarkshire,X0 ML1 5UH GBR ph: 44-0-20-7788-7414 fax: - nic.johnson@russopartnersllc.com http://www.viraxbiolabs.com

• General Corporate Information    Officers James Foster - Chief Executive Officer;Chairman and Director Nigel McCracken - Chief Operating Officer and Director Jason Davis - Chief Financial Officer Yair Erez - Director Evan Norton - Director Peer Information Virax Biolabs Group Limited (CORR.) Virax Biolabs Group Limited (RSPI) Virax Biolabs Group Limited (CGXP) Virax Biolabs Group Limited (BGEN) Virax Biolabs Group Limited (GTBP) Virax Biolabs Group Limited (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G9495L125 SIC: 2835 Fiscal Year Fiscal Year End: March Last Reported Quarter: - Next Expected EPS Date: 10/01/25 Share - Related Items Shares Outstanding: 4.34 Most Recent Split Date: 12.00 (0.10:1) Beta: 1.65 Market Capitalization: $3.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/01/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.71 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - 7.27 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - 7.13 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -97,994.00 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.26 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - 0.54 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - -

Powered by Zacks Investment Research ©